Consensus Repligen Corporation

Stocks

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 01:30:00 24/10/2026 am IST			5-day change	1st Jan Change
176.93 ^USD	-1.00%		+0.86%	+7.98%

19/10	Wall Street Hopes for a Relief Rally
19/10	Analyst recommendations: ConocoPhillips, Datadog, Intel, Fair Isaac, MGM Resorts…

Evolution of the Average Target: Repligen Corporation

Evolution of the Target Price: Repligen Corporation

Changes in Analyst Recommendations: Repligen Corporation

3194.g7JlkWEYLIEdd-nb5TWOnxozyndfDiv3-D6Bmo6uylc.y_MA5iA1WbB8Oq-Z1F3XyXlcpSIlZWzHkE_RqtvDpiPA5TLTD21P6G0EpA~5e39be2261dcaf30274b0ef2efab00ce

Analysts' recommendations: Repligen Corporation

19/10	Analyst recommendations: ConocoPhillips, Datadog, Intel, Fair Isaac, MGM Resorts…
09/09	UBS Adjusts Price Target on Repligen to $225 From $195, Keeps Buy Rating	MT
01/09	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
29/07	Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says	MT
29/07	RBC Raises Price Target on Repligen to $185 From $160, Keeps Outperform Rating	MT
29/07	Deutsche Bank Adjusts Repligen Price Target to $200 From $180, Maintains Buy Rating	MT
07/07	Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185	MT
15/05	Repligen Likely to Benefit From Diverse Growth Factors, RBC Says	MT
17/04	Rothschild & Co Redburn Initiates Repligen at Buy With $160 Price Target	MT
25/02	UBS Adjusts Price Target on Repligen to $195 From $200, Maintains Buy Rating	MT
16/01	UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating	MT
01/25/01	HSBC Initiates Repligen at Buy With $150 Price Target	MT
23/25/23	Repligen Shares Rise After Upgrade From Evercore ISI	MT
22/25/22	Evercore ISI Upgrades Repligen to Outperform From In Line, Price Target is $155	MT
03/25/03	RBC Lifts Price Target on Repligen to $205 From $204, Keeps Outperform Rating	MT
30/25/30	RBC Raises Price Target on Repligen to $204 From $193, Keeps Outperform Rating	MT
29/25/29	Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance	RE
01/25/01	RBC Lifts Price Target on Repligen to $193 From $191, Keeps Outperform Rating	MT
24/25/24	Barclays Initiates Repligen at Overweight With $150 Price Target	MT
30/25/30	RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating	MT
29/25/29	Wolfe Research Upgrades Repligen to Outperform From Peerperform	MT
08/25/08	RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating	MT
18/25/18	Evercore ISI Initiates Repligen at In Line With $155 Price Target	MT
21/25/21	RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating	MT
21/25/21	Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REPLIGEN CORPORATION					+13.86%
	ABBOTT LABORATORIES					+14.41%
	STRYKER CORPORATION					+18.06%
	MEDTRONIC PLC					+9.65%
	ESSILORLUXOTTICA					+19.16%
	CENCORA, INC.					+11.51%
	HOYA CORPORATION					+17.34%
	BECTON, DICKINSON AND COMPANY					-1.68%
	IDEXX LABORATORIES, INC.					+24.56%
	ALCON INC.					+29.13%
	Average					+15.60%
	Weighted average by Cap.					+14.89%